Get the Stockscreener App
22.82
5.09%
1.105
Alto Neuroscience Inc stock is traded at $22.82, with a volume of 205.50K.
It is up +5.09% in the last 24 hours and down -24.58% over the past month.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
See More
Previous Close:
$21.71
Open:
$21.92
24h Volume:
205.50K
Relative Volume:
0.29
Market Cap:
$895.31M
Revenue:
Net Income/Loss:
$-74.31M
P/E Ratio:
-9.1933
EPS:
-2.4817
Net Cash Flow:
$-62.86M
1W Performance:
-5.06%
1M Performance:
-24.58%
6M Performance:
-10.42%
1Y Performance:
+273.40%
1-Day Range:
$21.62
$23.31
1-Week Range:
$21.32
$25.25
52-Week Range:
$5.225
$37.48
Alto Neuroscience Inc Stock (ANRO) Company Profile
Name
Alto Neuroscience Inc
Sector
Industry
Phone
773-255-5012
Address
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
22.82 | 895.31M | 0 | -74.31M | -62.86M | -2.4817 |
VRTX
Vertex Pharmaceuticals Inc
|
509.86 | 129.23B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.75 | 94.92B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.00 | 82.36B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.32 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.60 | 42.04B | 5.76B | 514.49M | 1.10B | 4.4813 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-26 | Initiated | Wolfe Research | Outperform |
| May-05-26 | Initiated | BofA Securities | Buy |
| Jan-05-26 | Resumed | Chardan Capital Markets | Buy |
| Nov-17-25 | Initiated | BTIG Research | Buy |
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Oct-23-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Oct-23-24 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-03-24 | Initiated | Wedbush | Outperform |
| Feb-27-24 | Initiated | Jefferies | Buy |
| Feb-27-24 | Initiated | Robert W. Baird | Outperform |
| Feb-27-24 | Initiated | Stifel | Buy |
| Feb-27-24 | Initiated | TD Cowen | Outperform |
| Feb-27-24 | Initiated | William Blair | Outperform |
View All
Alto Neuroscience Inc Stock (ANRO) Latest News
Here's Why You Should Add ANRO Stock to Your Portfolio Now - Zacks Investment Research
At $2.32 a share, Alto Neuroscience (ANRO) CFO exercises options for 55,000 shares. - Stock Titan
Alto Neuroscience Insider Sold Shares Worth $3,567,247, According to a Recent SEC Filing - Moomoo
Alto Neuroscience(ANRO.US) Officer Sells US$3.57 Million in Common Stock - Moomoo
Form 4 Alto Neuroscience Inc For: 1 October By Investing.com - Investing.com South Africa
Form 4 Alto Neuroscience Inc For: 1 October By Investing.com - Investing.com Nigeria
Alto Neuroscience president and CFO Smith sells $3.57m in shares - Investing.com
Alto Neuroscience president and CFO Smith sells $3.57m in shares - Investing.com India
Exercising options at $2.35, Alto Neuroscience (ANRO)'s CFO sells shares. - Stock Titan
Alto Neuroscience President And CFO Sold Shares Worth Over $3.5M - TradingView
Stock options underpin an officer's proposed share sale at Alto Neuroscience (NYSE: ANRO). - Stock Titan
Alto Neuroscience, Inc.(NYSE: ANRO) added to S&P Global BMI Index - marketscreener.com
Alto Neuroscience Announces Participation in Upcoming September 2026 Investor Conferences - BioSpace
Alto Neuroscience announces September participation in investor conferences - Traders Union
Alto Neuroscience Announces Participation in Upcoming Investor Conferences - Business Wire
Alto Neuroscience Announces Participation in Upcoming Investor Conferences - Yahoo Finance
ANRO News | ALTO NEUROSCIENCE INC (NYSE:ANRO) - ChartMill
Alto Neuroscience Promotes Nick Smith to President and CFO - Contract Pharma
Alto Neuroscience Elevates Nicholas C. Smith to President and CFO with $6 Million Retention Deal - Kalkine Media
Nicholas C. Smith promoted to President and CFO at Alto Neuroscience - TradingView
Alto Neuroscience promotes Nick Smith to president and CFO By Investing.com - Investing.com India
Alto Neuroscience promotes Nick Smith to president and CFO By Investing.com - Investing.com Canada
Alto Neuroscience promotes Nick Smith to president and CFO By Investing.com - Investing.com UK
Alto Neuroscience, Inc. Promotes Nick Smith to President, Effective August 26, 2026 - marketscreener.com
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer - Yahoo Finance
Alto Neuroscience stock hits all-time high at 35.42 USD By Investing.com - Investing.com India
Alto Neuroscience stock hits all-time high at 35.42 USD - Investing.com
Alto Neuroscience stock hits all-time high at 35.42 USD By Investing.com - Investing.com UK
HC Wainwright Issues Optimistic Forecast for ANRO Earnings - MarketBeat
H.C. Wainwright Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $55 - Moomoo
H.C. Wainwright raises Alto Neuroscience price target to $55 - Investing.com India
H.C. Wainwright raises Alto Neuroscience price target to $55 - Investing.com
H.C. Wainwright raises Alto Neuroscience price target to $55 By Investing.com - Investing.com Canada
H.C. Wainwright raises Alto Neuroscience price target to $55 - Investing.com
Alto Neuroscience (NYSE:ANRO) Reaches New 1-Year High on Analyst Upgrade - MarketBeat
HC Wainwright Increases Alto Neuroscience (NYSE:ANRO) Price Target to $55.00 - MarketBeat
Is Alto Neuroscience (ANRO) Fully Valued As ALTO 207 Expands With New Funding? - Sahm
Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued? - Yahoo Finance
Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline? - Yahoo Finance
Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans - Yahoo Finance
Why Alto Neuroscience (ANRO) Is Up 13.5% After Expanding ALTO-207 Phase 3 And Securing New Funding - Sahm
Alto Neuroscience (ANRO) Slips 0.5% as Stock Holds Above Key $30.53 SupportFund Manager Survey - vinanet.vn
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC) - The Globe and Mail
Alto Neuroscience (ANRO) Slips 0.5% as Stock Holds Above Key $30.53 SupportCalendar Spread Trade - dars.gov.et
Alto Neuroscience (NYSE:ANRO) Upgraded to "Sell" at Wall Street Zen - MarketBeat
Alto Neuroscience (ANRO) investor group discloses 9.99% ownership cap - Stock Titan
Vestal Point Capital (ANRO) discloses 785,000-share Alto Neuroscience position in 13G/A - Stock Titan
BofA Securities Maintains Alto Neuroscience(ANRO.US) With Buy Rating - Moomoo
Why Alto Neuroscience (ANRO) Is Up 13.5% After Expanding ALTO-207 Phase 3 And Securing New Funding - simplywall.st
Alto Neuroscience (NYSE:ANRO) Stock Price Down 4.7%Here's Why - MarketBeat
Alto Neuroscience Inc Stock (ANRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alto Neuroscience Inc Stock (ANRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Smith Nicholas Conrad | PRESIDENT AND CFO |
Sep 30 '26 |
Option Exercise |
2.35 |
24,056 |
56,532 |
48,116 |
| Smith Nicholas Conrad | PRESIDENT AND CFO |
Sep 30 '26 |
Sale |
25.82 |
24,056 |
621,097 |
24,060 |
| Smith Nicholas Conrad | PRESIDENT AND CFO |
Sep 29 '26 |
Sale |
26.58 |
110,830 |
2,946,150 |
24,060 |
| NICHOLAS SMITH | Officer |
Sep 29 '26 |
Proposed Sale |
26.66 |
134,886 |
3,596,061 |
0 |
| Smith Nicholas Conrad | PRESIDENT AND CFO |
Sep 29 '26 |
Option Exercise |
2.35 |
110,830 |
260,450 |
134,890 |
1.39%
1.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):